Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;29(1):145-57.
doi: 10.1007/s11095-011-0521-7. Epub 2011 Jul 26.

Co-delivery of adenovirus and carmustine by anionic liposomes with synergistic anti-tumor effects

Affiliations

Co-delivery of adenovirus and carmustine by anionic liposomes with synergistic anti-tumor effects

Zhirong Zhong et al. Pharm Res. 2012 Jan.

Abstract

Purpose: To improve gene transducibility mediated by adenovirus (Ad) in cancer cells and further enhance anti-tumor effects by co-delivery.

Methods: Calcium-induced phase change method was used to prepare the complex of anionic liposomes and adenovirus (AL/Ad5). Gene expression was qualitatively detected by X-gal staining and quantitatively detected by ELISA. Taking adenovirus-mediated stromal cell-derived factor-1α (Ad5-SDF1α) as therapeutic gene and carmustine (BCNU) as chemotherapeutic agent, a co-delivering system of AL/Ad5-SDF1α/BCNU was prepared and administered to tumor-bearing mice by intratumor injection.

Results: Enhanced LacZ gene transduction was obtained in B16 and Lewis lung carcinoma cells in vitro and in vivo. Complexes of AL/Ad5-SDF1α improved SDF1α gene expression and led to accumulation of dendritic cells among the murine B16 melanoma cells in vivo. This co-delivery system of AL/Ad5-SDF1α/BCNU could significantly suppress tumor growth and prolong survival of tumor-bearing mice.

Conclusions: Through the co-delivering system, AL/Ad5-SDF1α could synergize with BCNU to improve the antitumor effect. It may be a promising strategy for solid tumor therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nanotechnology. 2010 Mar 12;21(10):105106 - PubMed
    1. Jpn J Cancer Res. 2000 Apr;91(4):363-7 - PubMed
    1. Semin Immunol. 2007 Feb;19(1):48-55 - PubMed
    1. Mol Ther. 2001 Jul;4(1):13-21 - PubMed
    1. J Virol. 2002 Feb;76(4):1892-903 - PubMed

Publication types

MeSH terms

LinkOut - more resources